| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2026-02-06 | 301509 | 我凯生材 | 35.43 | 5.70 | 201.95 机构专用 | | 中国中金财富证券 | | | | | | | | | 有限公司北京建国 | | | | | | | | | 门外大街证券营业 | | 2026-02-06 | 301509 | 金凯生材 | 35.43 | 5.70 | 201.95 机构专用 | नरे | 中国中金财富证券 | | | | | | | | | 有限公司北京建国 | | | | | | | | | 门外大街证券营业 | | | | | | | | नर | | | 2026-02-06 | 301509 | 金凯生科 | 35.43 | 5.70 | 201.95 机构专用 | | 中国中金财富证券 | | | | | | | | | ...

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2026-02-05 | 301509 | 金凯生科 | 35.50 | 5.70 | | 202.35 国投证券股份有限 | 中国中金财富证券 | | | | | | | | 公司河源分公司 | 有限公司北京建国 门外大街证券营业 | | | | | | | | | नर | 2月5日，金凯生科大宗交易成交5.7万股，成交额202.35万元，占当日总成交额的0.5%，成交价35.5元， 较市场收盘价38.48元折价7.74%。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

格隆汇1月30日丨金凯生科(301509.SZ)在投资者互动平台表示，公司储备的临床期项目涉及肿瘤、免疫 等多个疾病治疗领域，公司会严格按照信息披露规则披露项目信息。 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

格隆汇1月23日丨金凯生科(301509.SZ)公布，预计2025年归属于上市公司股东的净利润9,200万元～ 11,600万元，比上年同期增长138.28%～200.45%，扣除非经常性损益后的净利润7,200万元～9,100万 元，比上年同期增长314.69%～424.12%。 受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时受交付订单产品结构影 响，公司总体毛利率有所提高。以上综合因素导致公司2025年度业绩同比出现较大幅度提升。 ...

北京商报讯（记者 丁宁）1月23日晚间，金凯生科（301509）发布2025年业绩预告显示，预计2025年归 属净利润约为0.92亿元至1.16亿元，同比增长138.28%至200.45%。 金凯生科表示，受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时受交付订 单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司2025年度业绩同比出现较大幅度提 升。 ...

今夜又有多家A股上市公司发布业绩大幅预增公告。 新强联（300850）（300850）1月23日晚间发布公告称，预计2025年度归属于上市公司股东的净利润为 7.80亿—9.20亿元，比上年同期增长1093.07%—1307.21%。对于业绩变动的原因，公司表示，受益于风 电行业需求回暖，装机需求持续释放，公司依托技术优势进一步扩大了市场份额。在产能利用率保持较 高水平的背景下，公司通过优化成本管控、提升高附加值产品比重，实现了产品毛利率的稳步提高。此 外，报告期内非经常性损益预计对净利润的影响额约为9500万—11000万元，其中主要系持有金融资产 产生的公允价值变动损益以及处置金融资产产生的损益所致。 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东 | 盈利:78,000 万元-92,000 万元 | 盈利:6,537.77 万元 | | 的净利润 | 比上年同期增长:1093.07% - 1307.21% | | | 扣除非经常性损益后 | 盈利:68,000 万元-82,000 万元 | 盈利:14,906.42 万元 | | 的净利润 | 比 ...

Group 1 - New Strength Union (新强联) expects a net profit attributable to shareholders of 780 million to 920 million yuan for 2025, representing a year-on-year growth of 1093.07% to 1307.21, driven by the recovery in wind power demand and increased market share due to technological advantages [1] - Yongchuang Intelligent (永创智能) forecasts a net profit of 128 million to 155 million yuan for 2025, an increase of 721.57% to 894.86%, attributed to improved production and delivery management, along with a favorable product mix that enhanced gross margins [3] - Lianhua Technology (联化科技) anticipates a net profit of 350 million to 420 million yuan for 2025, reflecting a growth of 239.35% to 307.22%, supported by higher capacity utilization and foreign exchange gains from overseas subsidiaries [7] - Jinkai Biotechnology (金凯生科) projects a net profit of 92 million to 116 million yuan for 2025, indicating a year-on-year increase of 138.28% to 200.45%, driven by increased order deliveries and improved product mix affecting overall gross margins [8] - Shengen Technology (神工股份) expects a net profit of 90 million to 110 million yuan for 2025, a growth of 118.71% to 167.31%, due to the recovery in the global semiconductor market and increased demand for key materials in domestic markets [9]

Group 1 - The company, Jinkai Biotechnology, announced an expected net profit attributable to shareholders for the year 2025 ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [2]